miLens is as an electronics-free soft contact lens, intended for monitoring of intraocular pressure (IOP), that has shown superior accuracy and comfort compared to the Goldmann tonometer, the current gold standard for IOP measurement
miLens enables monitoring of intraocular pressure (IOP). (Credit: PRNewswire/Smartlens, Inc)
US-based ophthalmic technology company Smartlens has announced positive results for its non-invasive contact lens, miLens, from a clinical study conducted on 25 individuals.
miLens is as an electronics-free soft contact lens, intended for monitoring of intraocular pressure (IOP) in patients suffering from glaucoma and ocular hypertension.
The clinical study evaluated the accuracy and comfort of miLens, compared to the Goldmann tonometer, the current gold standard for IOP measurement.
Its results showed a statistically significant connection between IOP readings obtained by miLens and those measured using Goldmann applanation tonometry (GAT).
The company said that its miLens measured changes in IOP, consistent with the GAT IOP values, establishing its ability to monitor IOP over time.
In addition, 78% of miLens IOP measurements were within 2mmHg of the Goldmann applanation tonometry measures, showing a strong correlation between the two methods.
miLens is the smallest wearable microfluidic device available, said Smartlens.
Smartlens CEO Savas Komban said: “These strong clinical results for miLens represent a major step forward in the field of IOP monitoring. We believe that miLens has the potential to advance and transform glaucoma care by providing convenient and reliable IOP monitoring that can significantly improve patient outcomes.”
Glaucoma is a chronic eye disease that causes irreversible blindness, where elevated IOP is the primary and only treatable risk factor for this condition.
According to the World Health Organization (WHO) estimates, more than 50% of people with glaucoma are undiagnosed, and currently, over 76 million people suffering from the disease.
Smartlens said that miLens enables personalised treatments, monitoring treatment efficacy, and tracking patient compliance over time to prevent progression and irreversible vision loss.
In addition, the study participants reported high levels of comfort and ease of use, with no major adverse events reported, said the ophthalmic technology company.